StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) stock

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.44−1.12 (-3.92%)

Close on Nov 16, 2026Market cap $4.76BP/E –Yield –

Cogent Biosciences enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Cogent Biosciences's enterprise value was $4.25B on Nov 11, 2026, against $5.28B a year earlier. Over the last 5 years it ranged from $18.92M to $5.78B, with a median of $611.40M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$4.25B-7.9%
2025Dec 31, 2025$4.62B+778.2%
2024Dec 31, 2024$526.06M+131.4%
2023Dec 29, 2023$227.37M-56.0%
2022Dec 30, 2022$517.21M+275.4%
2021Dec 31, 2021$137.78M–
2020Dec 31, 2020-$10.77M–
2019Dec 31, 2019-$25.05M-130.9%
2018Dec 31, 2018$81.12M–

More Cogent Biosciences figures

See a number that looks wrong?